New practice-changing research will reduce the need for major surgery in many melanoma patients
9 June 2017
New findings from a large international clinical trial published in the New England Journal of Medicine this week are likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost. Many Australian patients participated in this trial, and Melanoma Institute Australia was the top recruiting centre in the world.
National and international melanoma management guidelines currently state that patients who are found to have melanoma deposits in a “sentinel” lymph node should undergo immediate completion lymph node clearance — a large operation that removes all remaining lymph nodes in the area (the axilla, the groin or the neck).
However, the initial results of the second Multicenter Selective Lymphadenectomy Trial (MSLT-II) indicate that there is no difference in survival for sentinel-node positive patients who undergo immediate lymph node clearance compared to those who are closely monitored with ultrasound to detect disease progression. The three-year melanoma-specific survival was 86±1.3% in 824 patients who had a completion lymph node dissection versus 86±1.2% in 931 patients who were monitored, after a median follow up of 43 months.
“These results are going to change treatment recommendations for sentinel-node positive patients, most of whom will avoid the short-term and long-term morbidity that may follow a complete lymph node dissection,” said co-author and Senior Surgeon at Melanoma Institute Australia, Professor John Thompson AO. “Only those who are found to have disease in their lymph nodes during the course of follow-up — about 20% — will ultimately require full regional lymph node dissection. This change in treatment recommendation is likely to improve the quality of life for many patients around the world.” In particular, this will make a big difference to patients who have disease of the lower limb, by reducing the rate of a common complication, lymphoedema.
Although immediate lymph node clearance in sentinel-node positive patients will no longer be recommended, an initial sentinel lymph node biopsy — a minor procedure able to be performed at the same time as wide excision of the primary melanoma site — will still be required to provide accurate staging and guide treatment planning, as well as to provide a reliable estimate of prognosis.
Although no significant survival benefit was achieved by immediate completion lymph node dissection, the authors noted that the procedure did provide some potential benefits for patients with melanoma, including improved staging which can help identify high-risk patients. As well, it provides information that may be required for inclusion in medical oncology clinical trials of new medical therapies, and improves regional disease control.
“The management of regional lymph nodes has long been controversial in the treatment of many solid tumours, particularly melanoma,” noted Professor Thompson. “But this trial provides robust evidence to change the current practice guidelines to improve our management of patients with melanoma.”
Publication: Faries MB, Thompson JF, Cochran AJ, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. N Engl J Med 2017; 376:2211-2222
MIA joins Sydney Health Partners
Sydney Health Partners' goal is to ensure world class research is successfully implemented & scaled-up to benefit patients & wider society.
Congratulations Dr Hansol Lee
Promising young MIA researcher conferred with University of Sydney PhD.
Olympians join forces for melanoma warning
Jana Pittman and Melinda Gainsford-Taylor urge Australians to be sun-safe and check their skin as they join the Game On Mole campaign in support of their much-loved coach
MIA research wins Cancer Institute of NSW 'Wildfire Highly Cited Publication'
Cited an incredible 427 times around the world, showing its vital role in improving outcomes for people with advanced melanoma.
Prof Richard Scolyer receives University of Tasmania Distinguished Alumni Award
Honouring the exceptional impact of his work on communities around the world.
MIA's Co-Medical Directors receive University of Sydney's Vice-Chancellor's Award for Outstanding Research
Awarded for their life-saving discoveries transforming melanoma patient care.
Aussies urged to mark start of summer by checking their skin
National day of action called amidst fears COVID lockdowns have deterred patients from seeking potentially life-saving medical treatment
Prof Georgina Long AO awarded the 2021 Ramaciotti Medal for Excellence in Biomedical Research
Recognising her pioneering work in immunotherapy in melanoma, transforming the care of patients worldwide.
AMC2021 conference wrap-up
Clinicians and researchers from across Australia and beyond united online, bringing the AMC2021 conference theme of Promising Futures to life.
Journalist and news reader Peter Overton our new National Ambassador
Melanoma Institute Australia is proud to announce that the Nine Network’s Peter Overton AM has joined us as a National Ambassador.
MIA researchers feature on prestigious Highly Cited Researchers 2021 List
MIA is proud to announce that five of our researchers have been named on the Clarivate Annual Highly Cited Researchers™ 2021 list.
New research into importance of skin surveillance to save lives from melanoma
New research shows routine skin checks by a health professional, coupled with checking your own skin, are vital in saving lives from melanoma.
Game On Mole - saving lives this summer
With new patient figures indicating people may have deferred skin checks during the pandemic our Game On Mole campaign is more important than ever.
Melanoma March physical events in 2022
We are excited to announce a return to our much-loved physical Melanoma March events in March 2022!
Community Fundraising Wrap Up July-Sept 2021
Read more about the wonderful MIA community fundraising initiatives held recently.
Australian researchers spearhead paradigm shift in melanoma treatment
Drug therapy set to become standard treatment in high-risk early stage patients to stop disease spread
Melanoma Bike Bash 2021: What a ride!
Over two fun, yet challenging, days in September an intrepid group of riders and crew successfully completed the annual Melanoma Bike Bash in WA!
Prof Georgina Long AO awarded inaugural Outstanding Female Researcher Medal from AAHMS
Prof Long AO has been recognised by Australian Academy of Health and Medical Sciences for her transformative work advancing melanoma treatments.
MIA researchers awarded $7.2m in NHMRC grants for health research
Three MIA researchers at University of Sydney received grants to further their important melanoma research.
Amie St Clair Ball in Wagga postponed for a third time
COVID restrictions continue to impact fundraising for melanoma services in Riverina.